These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 1976339)

  • 21. Decreased lymphocyte beta-adrenergic-receptor density in patients with heart failure and tolerance to the beta-adrenergic agonist pirbuterol.
    Colucci WS; Alexander RW; Williams GH; Rude RE; Holman BL; Konstam MA; Wynne J; Mudge GH; Braunwald E
    N Engl J Med; 1981 Jul; 305(4):185-90. PubMed ID: 6113543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The natural history of congestive heart failure: the Framingham study.
    McKee PA; Castelli WP; McNamara PM; Kannel WB
    N Engl J Med; 1971 Dec; 285(26):1441-6. PubMed ID: 5122894
    [No Abstract]   [Full Text] [Related]  

  • 23. Neurohormonal interactions and adaptations in congestive heart failure.
    Packer M
    Circulation; 1988 Apr; 77(4):721-30. PubMed ID: 3280156
    [No Abstract]   [Full Text] [Related]  

  • 24. Thrombolysis in Myocardial Infarction (TIMI) Trial--phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase.
    Rao AK; Pratt C; Berke A; Jaffe A; Ockene I; Schreiber TL; Bell WR; Knatterud G; Robertson TL; Terrin ML
    J Am Coll Cardiol; 1988 Jan; 11(1):1-11. PubMed ID: 3121710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of xamoterol a new beta-adrenoceptor partial agonist, in patients with angina pectoris.
    Barrios L; Geboers J; Piessens JH; de Geest H
    Eur J Clin Pharmacol; 1986; 29(6):667-71. PubMed ID: 2872055
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of xamoterol (ICI 118587), a new beta1 adrenoceptor partial agonist, on resting haemodynamic variables and exercise tolerance in patients with left ventricular dysfunction.
    Molajo AO; Bennett DH
    Br Heart J; 1985 Jul; 54(1):17-21. PubMed ID: 2861834
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are the clinical benefits of oral prenalterol in ischaemic heart failure due to beta blockade? A six month randomised double blind comparison with placebo.
    Glover DR; Wathen CG; Murray RG; Petch MC; Muir AL; Littler WA
    Br Heart J; 1985 Feb; 53(2):208-15. PubMed ID: 2857088
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of xamoterol, a beta 1 adrenoceptor partial agonist, in patients with ischaemic dysfunction of the left ventricle.
    Vigholt-Sørensen E; Faergeman O; Snow HM
    Br Heart J; 1989 Nov; 62(5):335-41. PubMed ID: 2574049
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The selectivity of xamoterol, prenalterol, and salbutamol as assessed by their effects in the presence and absence of ICI 118,551.
    McCaffrey PM; Riddell JG; Shanks RG
    J Cardiovasc Pharmacol; 1988 May; 11(5):543-51. PubMed ID: 2455840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mortality in heart failure: clinical variables of prognostic value.
    Cleland JG; Dargie HJ; Ford I
    Br Heart J; 1987 Dec; 58(6):572-82. PubMed ID: 2447925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ischaemic left ventricular failure: evidence of sustained benefit after 18 months' treatment with xamoterol.
    Vigholt-Sørensen E; Faergeman O
    Br Heart J; 1990 Sep; 64(3):186-9. PubMed ID: 1976339
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure.
    Marlow HF
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):23S-30S. PubMed ID: 2572251
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term studies with xamoterol in heart failure.
    Waller DG
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):53S-58S. PubMed ID: 2572255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Beta, partial agonists to treat heart failure: effects of xamoterol upon cardiac function and clinical status.
    Heng MK
    Clin Cardiol; 1990 Mar; 13(3):171-6. PubMed ID: 1969783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Review of clinical experience with xamoterol. Effects on exercise capacity and symptoms in heart failure.
    Marlow HF
    Circulation; 1990 Feb; 81(2 Suppl):III93-8. PubMed ID: 1967561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Xamoterol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Furlong R; Brogden RN
    Drugs; 1988 Oct; 36(4):455-74. PubMed ID: 2906865
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective beta-1-adrenoceptor partial agonist treatment for congestive heart failure.
    Shabetai R
    Cardiology; 1990; 77(5):357-66. PubMed ID: 1981492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The pharmacology of xamoterol: a basis for modulation of the autonomic control of the heart.
    Snow HM
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):3S-13S. PubMed ID: 2572252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficacy of xamoterol in heart failure of ischemic origin.
    Marlow HF
    J Cardiovasc Pharmacol; 1989; 14 Suppl 5():S69-72. PubMed ID: 2478814
    [No Abstract]   [Full Text] [Related]  

  • 40. The management of heart failure and the scope for new therapies: what role for xamoterol?
    Campbell RW
    Br J Clin Pharmacol; 1989; 28 Suppl 1(Suppl 1):59S-64S. PubMed ID: 2572256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.